Engineered deoxyribose-phosphate aldolases
US-11274286-B2 · Mar 15, 2022 · US
Engineered deoxyribose-phosphate aldolases
US11845968B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11845968-B2 |
| Application number | US-202217592869-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 4, 2022 |
| Priority date | Jul 9, 2018 |
| Publication date | Dec 19, 2023 |
| Grant date | Dec 19, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides engineered deoxyribose-phosphate aldolase polypeptides useful under industrial process conditions for the production of pharmaceutical and fine chemical compounds.
First claim
Opening claim text (preview).
We claim: 1. An engineered polynucleotide encoding an engineered deoxyribose-phosphate aldolase, wherein said engineered deoxyribose-phosphate aldolase comprises a polypeptide sequence having at least 95% sequence identity to SEQ ID NO: 2, or a functional fragment thereof, wherein said engineered deoxyribose-phosphate aldolase comprises a substitution in said polypeptide sequence of X145C/R/K, and wherein said engineered deoxyribose-phosphate aldolase has at 1.2 fold increase activity on (R)-2-ethynyl-glyceraldehyde compared to the deoxyribose-phosphate aldolase of SEQ ID NO:2, and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2. 2. The engineered polynucleotide encoding an engineered deoxyribose-phosphate aldolase of claim 1 , wherein said engineered deoxyribose-phosphate aldolase further comprises at least one substitution or set of substitutions in said polypeptide sequence at one or more positions selected from 2, 2/6/10/66/88/102/184/235/236, 2/6/102/141/203/235, 2/10/102/235/236, 2/47/66/71/141/184/203/235/236, 2/47/71/88/203/235/236, 2/47/71/141/197/235/236, 2/88/141/235/236, 2/203/235/236, 5, 6/203/235/236, 9, 10/47/66/184/197/236, 10/47/66/235/236, 10/47/71/184/203/235/236, 13, 13/46, 13/46/66/94, 13/46/66/94/184/204, 13/46/66/133/134/184, 13/46/66/184, 13/46/112/134/184, 13/46/133/184, 13/66/94, 13/66/94/184, 13/66/112/133/134/184/204, 13/66/112/133/134/204, 13/66/112/184, 13/66/133/134/184/204, 13/66/184/204, 13/94/133/184, 13/94/184, 13/94/184/204, 13/133/134/184, 13/133/134/204, 13/134/204, 13/184, 27, 40, 46/66/94/112, 46/66/112/133/134/184, 46/66/133/134, 46/66/133/184/197, 46/66/133/197, 46/66/134/184/197/204, 46/66/184, 46/112/133, 46/112/133/134/204, 46/133/204, 46/197/204, 47/66/71/88/203/235/236, 47/66/71/141/184, 47/66/88/184/235, 47/66/88/203/235/236, 47/66/141/235/236, 47/66/184/197/203/235/236, 47/66/184/197/236, 47/71/88/184/203/235, 47/71/88/184/203/236, 47/71/141/184/203/235, 47/71/184, 47/71/184/197/236, 47/71/184/235, 47/71/184/236, 47/88/102/141/235/236, 47/88/203/235/236, 47/88/235/236, 47/102/184/197/235/236, 47/102/203/235/236, 47/141/184, 47/141/184/236, 47/184/236, 47/203/235, 47/203/235/236, 47/203/236, 47/235/236, 62, 66, 66/88/102/184/197/203/235/236, 66/88/197, 66/88/235, 66/88/235/236, 66/94, 66/94/112/133/184, 66/94/112/184/204, 66/102/184/235/236, 66/112/133/134/197, 66/112/133/197, 66/112/134/197, 66/112/184, 66/133/184, 66/133/197, 66/184, 66/197/203/235, 84, 88, 88/102/141/184/235/236, 88/184, 88/184/197/203/235/236, 88/184/197/235/236, 88/184/203/235, 88/184/236, 88/197/235/236, 88/236, 94/112/184/197, 94/133/184, 96, 102/141/203, 102/184/203/236, 102/184/236, 102/197/235, 112, 112/133/134, 112/133/184/204, 112/134/197, 114, 115, 120, 127, 132, 133, 133/134/184, 141/184/203/235/236, 141/184/235, 141/197, 141/203/235/236, 141/236, 146, 148, 184, 184/203, 184/203/235, 184/203/236, 184/235/236, 184/236, 197/235, 203/235/236, 203/236, 204, 218, 235, 235/236, and 236, and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 6. 3. The engineered polynucleotide encoding an engineered deoxyribose-phosphate aldolase of claim 1 , wherein said engineered deoxyribose-phosphate aldolase further comprises at least one substitution or set of substitutions in said polypeptide sequence at one or more positions selected from 71/88/94/133, 71/133, and 133, and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 466. 4. The engineered polynucleotide encoding an engineered deoxyribose-phosphate aldolase of claim 1 , wherein said engineered deoxyribose-phosphate aldolase comprises a polypeptide sequence that is at least 95% identical to the sequence of at least one engineered deoxyribose-phosphate aldolase variant set forth in the even numbered sequences of SEQ ID NOs: 6, 12, 42, 104, 140-478. 5. The engineered polynucleotide encoding an engineered deoxyribose-phosphate aldolase of claim 1 , wherein said engineered deoxyribose-phosphate aldolase comprises a polypeptide sequence set forth in the even numbered sequences of SEQ ID NOs: 6, 12, 42, 104, 140-478. 6. The engineered polynucleotide sequence of claim 1 , wherein said engineered polynucleotide sequence comprises a sequence set forth in the odd numbered sequences of SEQ ID NOs: 5, 11, 41, 103, 139-477. 7. The engineered polynucleotide sequence of claim 1 , wherein said polynucleotide sequence is operably linked to a control sequence. 8. The engineered polynucleotide sequence of claim 1 , wherein said engineered polynucleotide sequence is codon optimized. 9. An expression vector comprising at least one polynucleotide sequence of claim 1 . 10. A host cell comprising at least one expression vector of claim 9 . 11. A host cell comprising at least one polynucleotide sequence of claim 1 . 12. A method of producing an engineered deoxyribose-phosphate aldolase in a host cell, comprising culturing the host cell of claim 11 , in a culture medium under suitable conditions, such that at least one engineered deoxyribose-phosphate aldolase is produced. 13. The method of claim 12 , further comprising recovering at least one engineered deoxyribose-phosphate aldolase from the culture medium and/or host cell. 14. The method of claim 13 , further comprising the step of purifying said at least one engineered deoxyribose-phosphate aldolase.
Assignees
Inventors
Classifications
- C12N9/88Primary
Lyases (4.) · CPC title
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title
having a known sequence of two or more amino acids, e.g. glutathione · CPC title
Deoxyribose-phosphate aldolase (4.1.2.4) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11845968B2 cover?
- The present invention provides engineered deoxyribose-phosphate aldolase polypeptides useful under industrial process conditions for the production of pharmaceutical and fine chemical compounds.
- Who is the assignee on this patent?
- Codexis Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N9/88. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).